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Positron emission tomography is so far the only method for 
in-vivo dose delivery verification in hadron therapy that is in 
clinical use. PET imaging during irradiation maximizes the 
number of detected counts and minimizes washout. In such a 
scenario, also short-lived positron emitters will be observed. 
As very little is known on the production of these nuclides, 
we determined which ones are relevant for proton therapy 
treatment verification. 
In order to be relevant, nuclides have to be produced close 
to the distal edge and thus at rather low proton energy. 
Therefore we measured the integral production of short-lived 
positron emitters in the stopping of 55 MeV protons in 
carbon, oxygen, phosphorus and calcium. The experiments 
were performed at the irradiation facility of the AGOR 
cyclotron at KVI-Center for Advanced Radiation Technology, 
University of Groningen. The positron emitters were 
identified based on their half-life. In order to do this, the 
proton beam was pulsed, i.e. delivered as a succession of 
beam-on and beam-off periods, and the time evolution of the 
511 keV positron annihilation photons was recorded. A half-
life analysis of the beam-off period allowed to determine the 
production rates of separate nuclides. The 511 keV photons 
were detected by a germanium clover detector [1]. A 
correction for the escape of positrons from the target, 
determined via Monte Carlo simulations, was applied. 
In the stopping of 55 MeV protons, the most copiously 
produced short-lived nuclides and their production rates 
relative to the relevant long-lived nuclides are: 12N (T1/2 = 
11 ms) on carbon (9% of the 11C production), 29P (T1/2 = 4.1 
s) on phosphorus (20% of the 30P production) and 38mK (T1/2 
= 0.92 s) on calcium (113% of the 38gK production). No short-
lived nuclides are produced on water (i.e. oxygen). The 
experimental production rates are used to calculate the 
production on PMMA and a representative set of 4 tissue 
materials. [fig. 1] The number of decays per 55 MeV proton 
stopped in these materials, integrated over an irradiation, is 
calculated as function of the duration of the irradiation. The 
most noticeable result is that for an irradiation in (carbon-
rich) adipose tissue, 12N will dominate the PET image up to 
an irradiation duration of 70 s. On bone tissue, 15O 
dominates over 12N after 8-15 s (depending on the carbon-to-
oxygen ratio). Considering nuclides created on phosphorus 
and calcium, the short-lived ones provide 2.5 times more 
decays than the long-lived ones during a 70 s irradiation. 
Bone tissue will thus be better visible in beam-on PET 
compared to PET imaging after an irradiation. 
The results warrant detailed investigations into the energy-
dependent production of 12N, 29P and 38mK and their effect 
on PET imaging during proton irradiations. 
 
Figure 1: Number of decays of PET nuclides per 55 MeV 
proton stopped and integrated over an irradiation, as 
function of the duration of the irradiation for adipose, 
skeletal muscle, compact bone and cortical bone tissue. 
Short-lived nuclides are shown with solid lines, long-lived 
ones with dashed lines 
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Positron emission tomography is so far the only method for 
in-vivo dose delivery verification in hadron therapy that is in 
clinical use. A PET scanner placed in the treatment position 
(in-situ) will be able to obtain the highest number of counts, 
as it minimizes the decay of the positron emitting nuclei 
before the scan is started as well as reduces the effect of 
biological washout. We investigated the influence of the scan 
protocol, i.e. the moment when a scan in done in relation to 
the treatment delivery, on the ability to measure 
unacceptable deviations from the treatment plan. 
We developed a Geant4-based Monte-Carlo framework for 
proton therapy simulations. Four patient cases are studied: 
two head-and-neck, one sarcoma near the spine, and one 
breast cancer case. For each irradiation field, the production 
of the following PET isotopes is calculated: 15O, 11C, 10C, 
14O, 30P, 38K, and 13N. The time sequence of the pencil 
beam scanning irradiation, the decay of the PET isotopes 
during the irradiation, and biological washout are included in 
the simulation. The production of these nuclei is then used to 
calculate a PET image for two scan protocols: a scan of 120 
seconds after the first field, or a scan of 120 seconds after 
the last field. To mimic a typical scanner spatial resolution, 
the images are blurred using a Gaussian blurring function 
with 4 mm FWHM.  
Deviations from the treatment plan are simulated by shifting 
the patient 4 mm perpendicular to the field angle, or by 
increasing the patient density by 3%. The PET image is then 
simulated again for each scanning protocol. The ability of 
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each protocol to detect these deviations from the treatment 
plan is investigated by comparing the planned and the 
modified PET image. Several analysis methods are used: line 
profiles coupled to the field-directions, structural similarity 
index analysis [1], and gamma index analysis. [2]  
Preliminary data shows that a difference in density is best 
detected by starting the scan directly after the first field. 
However, shifts perpendicular to the field directions are 
better detected when the scan is done after the last field, 
due to the increased activity and counting-rate. 
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Purpose: Adaptive radiotherapy aims to synchronize the 
treatment beam with the tumour motion. It requires the 
prediction of respiratory motion which has received much 
attention for over a decade. The performance of prediction 
algorithms to the dose delivery to the tumour is evaluated for 
the first time in terms of CTV-PTV margin.  
Methods and Materials: Clinical tumour volume (CTV) is 
outlined in treatment planning and is aimed to be irradiated 
with sufficient dose. Owing to uncertainties including 
respiration-induced motion, a sufficient margin around CTV is 
defined to form planning target volume (PTV). PTV is 
irradiated to ensure sufficient dose delivery to CTV, whereas 
CTV-PTV margin should be minimal to avoid irradiating 
normal tissues outside CTV. In this work, we adopt tumour 
control probability (TCP) to quantify sufficient dose delivery 
using TCP model based on Poisson statistics. The CTV-PTV 
margin required to yield 90% TCP is evaluated for no 
prediction (a baseline algorithm that refers to using the 
current measurement as a lookahead prediction.) and 
recently proposed EKF-GPRN prediction algorithm [1] at 
lookahead lengths of 192 ms, 384 ms and 576 ms. 
A large database of 304 three dimensional respiratory motion 
traces from a group of 31 patients is employed to evaluate 
algorithms. We assume that a spherical-shaped CTV with a 
radius of 2.5 mm undergoes 3-D motion along these traces. 
Algorithms are used to predict the center of CTV and the 
prediction error is considered as the deviation of treatment 
beam from the CTV.  
Results: Patient-wise statistics for CTV-PTV margin required 
to achieve 90% TCP are given for each algorithm in the 
following table. The values in the parenthesis are percent 
ratios relative to no prediction. The results show that EKF-
GPRN reduces the required CTV-PTV margin to around 20% on 
average, compared to no prediction across all the lookahead 
lengths. It indicates that EKF-GPRN can significantly improve 
dose conformality and effectively reduce normal tissue 
exposure. 
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Purpose: Tumor hypoxia is linked to poor prognosis, but 
personalized hypoxic intervention with radiosensitizers (e.g., 
nimorazole), bioreductive drugs or dose escalation to hypoxic 
tumor volumes may improve outcome. Hypoxia-selective PET 
tracers like FMISO and FAZA are available, but inherent 
weaknesses of PET in general (low resolution) and hypoxia 
PET in particular (low image contrast due to slow tracer 
retention and clearance) may compromise the quantitative 
accuracy and reproducibility of hypoxia PET. 
Methods: To assess the severity of this problem, and refine 
and optimize scan protocols to overcome them, various 
human and rodent tumors were established in mice.  
Subsequently, mice were scanned using different scan 
protocols on a high-resolution (~1 mm) Mediso nanoPET/MRI. 
Some mice were scanned dynamically for 3-hours to allow 
full pharmacokinetic analysis (PET imaging gold standard) 
followed by tumor dissection, cryosectioning and high-
resolution analysis of tracer distribution (autoradiography) 
and hypoxia (pimonidazole), on multiple tissue sections 
covering the whole tumor volume. Other mice were scanned 
statically at two different post-injection (PI) time points, to 
mimic the image contrast obtainable clinically (1.5h PI) and a 
much better contrast (3h PI), which can only be obtained in 
rodents due to rapid clearance of unbound tracer in 
organisms with high metabolic rates. On the next day, the 
same mice were scanned again at 1.5h PI or at 1.5 and 3h PI 
followed by invasive tissue analysis as described above. 
Results/Conclusions: An analysis of the distribution of FAZA 
(autoradiograms) and hypoxia (pimonidazole) on tissue 
sections revealed that 3h PI static scans, provide highly 
accurate spatial information on hypoxia, and thus serve as a 
gold standard. Despite a dramatic increase in inter-tissue and 
intra-tumoral image contrast at late scan times (3h PI), a 
voxel-by-voxel comparison revealed an excellent correlation 
between early (1.5h) and delayed (3h) scans. In addition, the 
day-to-day spatial reproducibility (overall tracer uptake and 
its spatial distribution) was good, even when scans were 
acquired at a clinical achievable contrast. Taken together, 
these results suggest that target definition is reasonable 
robust and reliable at a clinical achievable contrast. In 
contrast a simplified, and thus clinically feasible, dynamic 
model that both integrates information on blood flow/tracer 
wash-in (deduced from the FAZA signal during the first 15 
min of the scan) and tracer retention (deduced at 1.5 h PI), 
was unexpectedly less reliable, in terms of hypoxia-
specificity, than the uncorrected low-contrast static scan. 
This may relate to an uncoupling between blood flow and 
oxygen delivery capacity in the abnormal tumor vasculature. 
Whether, similar limitations apply to full dynamic scans are 
currently being investigated, using a variety of differing 
pharmacokinetic models.  
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